Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | EBP | Q15125 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13659614 | 1.00 | SIGMAR1 (0.47) | SIGMAR1EBPKDM4EALDH1A1TSHR | |
| SCHEMBL19226525 | 0.89 | SIGMAR1 (0.53) | SIGMAR1EBPKDM4EALDH1A1TSHR | |
| SCHEMBL19226608 | 0.78 | USP2 (0.36) | KDM4EALDH1A1TSHRPOLBKMT2A | |
| SCHEMBL18774761 | 0.78 | USP2 (0.36) | KDM4EALDH1A1TSHRPOLBKMT2A | |
| SCHEMBL18774762 | 0.78 | USP2 (0.36) | KDM4EALDH1A1TSHRPOLBKMT2A | |
| SCHEMBL24134163 | 0.78 | SIGMAR1 (0.52) | SIGMAR1EBPKDM4EKMT2AMEN1 | |
| SCHEMBL17888412 | 0.78 | SIGMAR1 (0.52) | SIGMAR1EBPKDM4EKMT2AMEN1 | |
| SCHEMBL14996110 | 0.78 | SIGMAR1 (0.52) | SIGMAR1EBPKDM4EKMT2AMEN1 | |
| SCHEMBL18233582 | 0.76 | DPP4 (0.33) | — | |
| SCHEMBL20551208 | 0.76 | SIGMAR1 (0.50) | SIGMAR1EBPKDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | SIGMAR1 1063/4885EBP 3909/4885KDM4E 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.